Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. develops gene-edited cell and gene therapies as a clinical-stage biotechnology company. Its recurring news centers on allogeneic CAR T immunotherapies in oncology, including off-the-shelf, gene-edited CAR T-cell product candidates, and on broader gene therapy research using its gene-editing platform and in-house manufacturing capabilities.
Company updates commonly cover clinical and partner-program developments for candidates such as lasme-cel, eti-cel and cema-cel; TALE-based and epigenetic editing research; financial results and business updates; collaborations and license arrangements; and monthly disclosures of share capital and voting rights for its Euronext Growth listing alongside its Nasdaq-listed ADS trading under CLLS.
Cellectis (NASDAQ: CLLS, Euronext Growth: ALCLS) announced it will report its second quarter 2026 financial results, for the period ended June 30, 2026, on Thursday, August 6, 2026 after the close of the US market. The earnings press release will be available in the Investors section of the company’s website.
Cellectis noted it will not host a conference call to discuss these results. Investor questions can be directed to the company’s investor relations team at investors@cellectis.com. Cellectis is a clinical-stage biotechnology company focused on allogeneic CAR T immunotherapies and gene therapies, with headquarters in Paris and additional locations in New York and Raleigh.
Cellectis (CLLS) released its monthly information on share capital and voting rights under Article 223-16 of the French financial markets authority rules.
As of June 30, 2026, Cellectis reported 100,698,158 shares outstanding and a total of 105,551,650 voting rights on Euronext Growth.
Cellectis (NASDAQ: CLLS, Euronext Growth: ALCLS) held its shareholders general meeting on June 25, 2026, in Paris at 2:30 p.m. CET.
Approximately 55.84% of voting rights were exercised. Resolutions 1 through 29 were adopted, while resolution 30 was rejected, aligning with the board’s recommendations.
Cellectis (NASDAQ: CLLS) reported final Phase 1 BALLI-01 results for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia and preliminary NATHALI-01 data for eti-cel in relapsed/refractory B-cell non-Hodgkin lymphoma at EHA 2026.
Lasme-cel achieved 100% ORR (7/7) in the target Phase 2 population, with 57% CR/CRi and 75% MRD-negative among responders; all proceeded to HSCT. ≥grade 3 CRS and ICANS each occurred in 4% of patients, IEC-HS in 2%, all resolving. Eti-cel showed 88% ORR and 63% CR in the optimal dose cohort, with alemtuzumab exposure and low-dose IL-2 being explored to optimize lymphodepletion and CAR-T expansion. Both BALLI-01 pivotal Phase 2 and NATHALI-01 Phase 1 are open for recruitment, with key analyses expected in Q4 2026.
Cellectis (NASDAQ: CLLS) received FDA RMAT designation for lasmecabtagene timgedleucel (lasme-cel), a CD22-targeting allogeneic CAR-T candidate for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
The designation is based on Phase 1 BALLI-01 data and supports the ongoing pivotal Phase 2 BALLI-01 trial, which is open for enrollment.
Cellectis (CLLS) reported its monthly share capital and voting rights information for Euronext Growth.
As of May 31, 2026, the company had 100,691,658 shares outstanding and a total of 106,134,467 voting rights (ISIN: FR0010425595).
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company, will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
The notice of meeting is available on Cellectis’ investor website.
Cellectis (NASDAQ: CLLS) will present new clinical data on its allogeneic CAR-T candidates lasme-cel and eti-cel at the EHA 2026 congress in Stockholm, June 11–14, 2026.
Presentations cover full Phase 1 BALLI-01 data in r/r B-ALL and preliminary Phase 1 NATHALI-01 data in r/r B-NHL, with broader datasets expected in Q4 2026.
Summary not available.
Cellectis (Euronext Growth: CLLS) published its monthly statement of share capital and voting rights as of 04/30/2026. The table shows a total of 100,611,481 shares and 106,021,715 total voting rights.
Contact details for media and investor relations are provided.